We are live on ! Find out more
ORMP icon

Oramed Pharmaceuticals
ORMP

8 hedge funds and large institutions have $188K invested in Oramed Pharmaceuticals in 2013 Q2 according to their latest regulatory filings, with 8 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
8
Holders Change
+8
Holders Change %
–
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
1
Credit Suisse
Switzerland
$125K +$126K +15,272 New
FNBT
2
FineMark National Bank & Trust
Florida
$28K +$28.6K +3,473 New
Wells Fargo
3
Wells Fargo
California
$11K +$11.2K +1,358 New
TRCT
4
Tower Research Capital (TRC)
New York
$9K +$9.06K +1,100 New
MA
5
MUFG Americas
New York
$7K +$6.87K +834 New
HRIA
6
Haberer Registered Investment Advisor
Ohio
$3K +$2.75K +334 New
U
7
UBS
Switzerland
$3K +$3.44K +417 New
Royal Bank of Canada
8
Royal Bank of Canada
Ontario, Canada
$2K +$1.65K +200 New

ORMP Hedge Fund Activity: Q2 2013 in Review

8 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q2 2013, worth a combined $188K.

Buyers outnumbered sellers: 8 funds opened new ORMP positions and 0 closed out — a net gain of 8 holders — while 0 added to existing stakes and 0 trimmed.

  • 8 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $188K of Oramed Pharmaceuticals stock for Q2 2013.
  • 8 funds opened new Oramed Pharmaceuticals positions in Q2 2013 and 0 closed out, a net change of +8 holders.

Based on aggregated 13F filings for Q2 2013.